KYTX Kyverna: רווח למניה בשנים עשר החודשים האחרונים

Kyverna Therapeutics (KYTX) is implementing CAR-T technologies for the treatment of sclerosis, enhancing the process with software-driven dosage control. The net income per share over the last 12 months on the GURU.Markets terminal linear chart visualizes this trend, where -2.78 captures the value of this parameter. Meanwhile, the robotization of bioreactors is supplemented by the mandatory participation of physicians during the collection of biomaterials.
פילוחים אנליטיים ודוחות נתונים של חברת Kyverna Therapeutics, Inc (KYTX)

Net income per share over 12 months measures the proportional share of the company's total financial result distributed across the entire security issue over a rolling year to assess the actual return on equity. By analyzing the trend of the 12-month net income per share, an investor can see the impact of clinical adaptation costs for Kyverna Therapeutics (KYTX) therapy, which confirms strong institutional support for the asset.